News

  • INTEGRAGEN – RÉSULTATS ANNUELS 2019

    INTEGRAGEN - ANNUAL RESULTS 2019

    Sales growth (+201TP3Q), positive EBITDA in the second half and close to breakeven for the full year IntegraGen today announced its financial results for the year ended... Read More

  • INTEGRAGEN ANNONCE UN ACCORD AVEC UN CENTRE DE CANCÉROLOGIE US DE RÉFÉRENCE POUR L’UTILISATION DE MERCURY™, L’OUTIL D’INTERPRÉTATION ET DE REPORTING DES DONNÉES DE SÉQUENÇAGE EN CANCÉROLOGIE

    INTEGRAGEN ANNOUNCES AN AGREEMENT WITH A LEADING US CANCER CENTER FOR THE USE OF MERCURY™, THE ONCOLOGY SEQUENCING DATA INTERPRETATION AND REPORTING TOOL

    IntegraGen announced today that the Dana Farber Cancer Institute will use MERCURYTM, IntegraGen's proprietary software, in their analysis and reporting of tumor sequencing data... Read More

  • COVID-19: MEASURES TO PROTECT EVERYONE AND ENSURE YOUR PROJECTS RUN SMOOTHLY

    Dear IntegraGen customers and partners, We care about your satisfaction and understand that the entire community is impacted by COVID-19. That's why we're working hard to maintain... Read More

  • INTEGRAGEN NOMINATED FOR THE GALIEN MEDSTARTUP AWARD 2018

    IntegraGen has been nominated for the Prix Galien MedStartup 2018, a joint initiative between the... Read More

  • GOPATH LABORATORIES ANNOUNCE THE LAUNCH OF THE MIR-31NOW TEST

    GoPath Laboratories today announced the launch of a new proprietary test, miR31nowTM, to coincide with... Read More

  • INTEGRAGEN PARTICIPATES IN THE ASCO 2018 AMERICAN CANCER CONGRESS HELD IN CHICAGO FROM JUNE 1 TO 5

    The annual ASCO meeting brings together more than 32,000 cancer specialists from around the world to... Read More

  • PUBLICATION IN BIOMARKER INSIGHTS OF TECHNICAL VALIDATION DATA FOR THE MIR-31-3P TEST

    IntegraGen is pleased to announce that a full summary of the results of the validation studies for... Read More

en_US